Vynleads Inc. Announces the Launch of its AI‑Powered “Done With Diabetes™” App
Vynleads Inc. (OTCQB: VYND), a U.S. company listed on the OTC Bulletin Board, unveiled its new digital wellness platform, Done With Diabetes™, on February 11, 2026. The mobile‑first application is designed to provide adults with type 2 diabetes, prediabetes, or broader metabolic health objectives with daily, AI‑driven guidance and community support.
How the Platform Works
The app combines several components to foster sustainable lifestyle changes:
| Feature | Description |
|---|---|
| 8‑Week Success Blueprint | A structured program that introduces core habits and tracks progress. |
| Dr. Smith AI Wellness Coach | Personalized coaching messages that adapt to a user’s performance and data inputs. |
| AI Agent‑Powered Community Support | Peer interaction moderated by AI agents that encourage accountability and knowledge sharing. |
| Lifetime Wellness Mode | An ongoing, AI‑generated routine that helps users maintain momentum after the initial program. |
According to Alex Mannine, Co‑Founder and CEO of Vynleads, the goal of Done With Diabetes™ is to translate the principles of lifestyle medicine into a practical, day‑by‑day experience. “We designed this platform for the reality of diabetes—it’s managed day by day,” Mannine said. “Done With Diabetes™ gives people a clear plan they can follow, with personalized guidance that adapts as they build momentum, plus a Community supported by AI Agents and peers so no one feels alone between appointments.”
Market Context
Vynleads operates on the OTC Bulletin Board, a less visible U.S. exchange, and currently trades at $0.31609 per share (as of 2026‑02‑09). Its 52‑week high and low are $0.5299 and $0.252, respectively. With a market capitalization of approximately $9.16 million and a price‑earnings ratio of –21.62, the company’s valuation reflects its early‑stage status and ongoing product development.
The launch of Done With Diabetes™ represents a significant milestone in Vynleads’ strategy to monetize its AI capabilities. By addressing a large, growing market—type 2 diabetes affects more than 30 million Americans—the company aims to generate recurring revenue through subscription models and potential data‑driven partnerships.
Industry Implications
The move aligns with a broader industry trend in which technology firms are expanding into personalized health management. AI‑powered coaching platforms are increasingly seen as a cost‑effective complement to traditional medical care, offering continuous support that can improve adherence to lifestyle changes. Vynleads’ entry into this space positions it alongside other digital health startups that leverage data analytics to optimize patient outcomes.
Future Outlook
While the company has yet to report revenue figures for the new app, the official launch is expected to attract a sizeable user base, particularly given the rising prevalence of metabolic disorders. Investors and analysts will likely monitor user acquisition metrics, subscription conversion rates, and engagement statistics as key indicators of the platform’s commercial viability.
For now, Vynleads continues to build on its foundation of AI‑driven wellness solutions, reinforcing its commitment to turning complex health data into actionable, everyday guidance.
